Personal CFO Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $506K | Sell |
1,137
-22
| -2% | -$9.79K | 0.09% | 221 |
|
|
2025
Q1 | $562K | Buy |
1,159
+92
| +9% | +$44.6K | 0.11% | 192 |
|
|
2024
Q4 | $430K | Buy |
1,067
+380
| +55% | +$153K | 0.08% | 230 |
|
|
2024
Q3 | $320K | Buy |
687
+24
| +4% | +$11.2K | 0.04% | 399 |
|
|
2024
Q2 | $311K | Sell |
663
-2
| -0.3% | -$937 | 0.05% | 365 |
|
|
2024
Q1 | $278K | Sell |
665
-324
| -33% | -$135K | 0.04% | 420 |
|
|
2023
Q4 | $402K | Sell |
989
-74
| -7% | -$30.1K | 0.07% | 286 |
|
|
2023
Q3 | $370K | Buy |
1,063
+284
| +36% | +$98.8K | 0.07% | 270 |
|
|
2023
Q2 | $274K | Sell |
779
-69
| -8% | -$24.3K | 0.06% | 350 |
|
|
2023
Q1 | $267K | Sell |
848
-102
| -11% | -$32.1K | 0.06% | 348 |
|
|
2022
Q4 | $274K | Buy |
950
+2
| +0.2% | +$578 | 0.06% | 329 |
|
|
2022
Q3 | $274K | Buy |
948
+3
| +0.3% | +$867 | 0.07% | 271 |
|
|
2022
Q2 | $266K | Sell |
945
-801
| -46% | -$225K | 0.06% | 297 |
|
|
2022
Q1 | $456K | Buy |
1,746
+822
| +89% | +$215K | 0.09% | 214 |
|
|
2021
Q4 | $203K | Buy |
+924
| New | +$203K | 0.04% | 444 |
|
|
2021
Q2 | – | Sell |
-1,342
| Closed | -$288K | – | 470 |
|
|
2021
Q1 | $288K | Buy |
1,342
+453
| +51% | +$97.2K | 0.06% | 270 |
|
|
2020
Q4 | $210K | Buy |
889
+7
| +0.8% | +$1.65K | 0.05% | 342 |
|
|
2020
Q3 | $0 | Buy |
882
+149
| +20% | – | ﹤0.01% | 326 |
|
|
2020
Q2 | $213K | Buy |
+733
| New | +$213K | 0.06% | 277 |
|